MENLO PARK, Calif.,
March 13, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, will share scientific data at the 55th Annual
Meeting of the Society of Toxicology (SOT), which will suggest the
company's novel topical gel BPX-01 delivers acne-fighting
medication to the target area safely without systemic side
effects.
A poster on the research, titled "BPX-01 Toxicological
Evaluation of 1% Topical Minocycline Gel," will be presented at
the Baltimore meeting from
1:15 p.m. to 4:30 p.m. on
March 14 (poster number P511). The
SOT meeting is one of the world's largest gatherings of
toxicologists.
Oral minocycline is a routinely prescribed antibiotic for the
treatment of acne, but because it delivers the active drug
systemically, there can be undesirable side effects, such as upset
stomach, diarrhea, dizziness and headache. BPX-011 is
the first fully solubilized and stable topical gel formulation of
minocycline, which had previously been demonstrated to penetrate
the skin and to the pilosebaceous unit where acne develops. BPX-01
may improve bioavailability and enable the use of a lower dosage of
the drug, which pre-clinical and clinical studies suggest thus far
does not enter the blood system in measurable quantities.
"One of the issues that concerns me the most with our current
treatment options for moderate-to-severe acne is the systemic
exposure to antibiotics, which can lead to antibiotic resistance
and other unwanted side effects," said Dr. Joely Kaufman, board certified dermatologist and
investigator for the BioPharmX Phase 2b study of BPX-01. "In my
practice I try to minimize the length of time a patient is on oral
antibiotics to avoid systemic side effects."
"The research to date suggests that BPX-01 topical gel delivers
low but potentially efficacious dosages of minocycline to target
areas," said Kin F. Chan, executive vice president of research and
technology at BioPharmX. "BPX-01 offers promise to millions of
people who cannot take oral minocycline to treat their acne,
including young children, pregnant women and the many people who
are intolerant of systemic antibiotic treatments."
This is the second year BioPharmX is appearing at the SOT
meeting. Last year, company researchers shared non-clinical safety
and toxicokinetic data for BPX-01. This year's presentation
provides an overview of the non-clinical program with special focus
on the study data from longer drug exposures with comparisons to
the earlier data.
BioPharmX is currently conducting the OPAL (tOPicAL Minocycline
Gel) study – a Phase 2b dose finding clinical trial to assess the
efficacy and safety of BPX-01 for the treatment of acne vulgaris.
The 12-week, multi-center, randomized, double-blind, three-arm,
vehicle-controlled study involves 225 individuals, aged 9 to 40,
who have moderate-to-severe inflammatory, non-nodular acne
vulgaris.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million Americans. The U.S. market for prescription acne
medications is estimated at $4
billion.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company that seeks to provide products through proprietary platform
technologies for prescription, over-the-counter and supplement
applications in dermatology and women's health. To learn more about
BioPharmX, visit
www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions and strategies,
including, but not limited to, statements regarding, the safety and
medical effects of BPX-01, the effect BPX-01 may have on the
treatment of acne, whether minocycline's anti-inflammatory
properties may be delivered in a topical formulation to target P.
acnes-stimulated sebocytes, commencement and results of future
tests involving BPX-01, continued and consistent results in future
tests of BPMX-01 and absence of side effects of future use of
BPX-01. These forward-looking statements may be identified by words
such as "may", "plan", "expect," "anticipate," "believe," or
similar expressions that are intended to identify such
forward-looking statements. These forward-looking statements
involve risks and uncertainties, as well as assumptions, which, if
they do not fully materialize or prove incorrect, could cause our
results to differ materially from those expressed or implied by
such forward-looking statements. The risks and uncertainties
include those described in the company's filings with the
Securities and Exchange Commission. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking statements
included in this news release are made only as of the date hereof
and the company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
1 Caution: BPX-01 is a new drug limited by U.S. law to
investigational use.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-society-of-toxicology-poster-suggests-promise-of-bpx-01-as-topical-acne-therapy-highlights-safety-300420956.html
SOURCE BioPharmX Corporation